bisantrene has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fountzilas, G; Lim, LO; Yunis, AA | 1 |
| Cullinan, SA; Kvols, LK; Laurie, JA; Mailliard, JA; Marschke, RF; O'Connell, MJ; Tschetter, LK | 1 |
2 other study(ies) available for bisantrene and Pancreatic Neoplasms
| Article | Year |
|---|---|
Sensitivity of human pancreatic carcinoma cell line (MIA PaCa-2) to Bisantrene and Theprubicin in vitro.
Topics: Anthracenes; Antibiotics, Antineoplastic; Cell Division; Cell Line; DNA; Doxorubicin; Humans; Pancreatic Neoplasms | 1984 |
Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anthracenes; Antineoplastic Agents; Drug Evaluation; Infusion Pumps; Pancreatic Neoplasms; Remission Induction; Time Factors | 1988 |